Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) is expected to post its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.
Monogram Orthopaedics (NASDAQ:MGRM - Get Free Report) last announced its earnings results on Wednesday, March 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.03. On average, analysts expect Monogram Orthopaedics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Monogram Orthopaedics Stock Up 0.7 %
Shares of MGRM stock traded up $0.02 during trading hours on Friday, hitting $2.69. 50,439 shares of the company's stock traded hands, compared to its average volume of 247,568. Monogram Orthopaedics has a 12-month low of $1.84 and a 12-month high of $4.21. The stock has a market cap of $94.93 million, a price-to-earnings ratio of -5.72 and a beta of 0.74. The stock's fifty day simple moving average is $2.73 and its two-hundred day simple moving average is $2.54.
Wall Street Analyst Weigh In
Several research firms have recently issued reports on MGRM. Roth Mkm lifted their price target on Monogram Orthopaedics from $4.00 to $5.40 and gave the stock a "buy" rating in a research report on Tuesday, March 18th. Roth Capital set a $5.40 target price on shares of Monogram Orthopaedics in a research note on Tuesday, March 18th.
View Our Latest Stock Report on MGRM
About Monogram Orthopaedics
(
Get Free Report)
Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.
Further Reading
Before you consider Monogram Orthopaedics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monogram Orthopaedics wasn't on the list.
While Monogram Orthopaedics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
